SCHEMBL2849543

SCHEMBL2849543

C=Cc1ccccc1COc1cc(C=O)c(O)c(C=O)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 9/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
PTPRC P08575 1/20 0.34
PTPN1 P18031 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8625765 0.78 ALDH1A1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL11055202 0.77 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1HPGDHTTPTGDR2
SCHEMBL8625003 0.77 NPC1 (0.64) NPC1RAB9AALDH1A1HTTKDM4E
SCHEMBL11215052 0.76 SMN1; SMN2 (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL23680091 0.76 RAB9A (0.46) ERN1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL16406152 0.76 HMGB1 (0.40) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL2854281 0.75 ERN1 (0.42) ERN1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL28510243 0.74 RAB9A (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL8163506 0.73 F2 (0.41) NPC1RAB9ASMN1; SMN2KDM4EPTPRC
SCHEMBL9155982 0.73 RAB9A (0.56) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204038-A1 Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid CARLONI SILVIA 2010-08-12 US disclosed
EP-1765496-B1 CATALYSTS BASED ON COPPER COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA SPA (IT) 2010-07-14 EP disclosed
US-7723539-B2 Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid ENDURA S.P.A. (IT) 2010-05-25 US disclosed
US-20080021237-A1 Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid ENDURA S.P.A. (IT) 2008-01-24 US disclosed
EP-1765496-A1 CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA S.p.A. (IT) 2007-03-28 EP disclosed
WO-2005123254-A1 CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA S.P.A. (IT) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021237-A1 Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid SCO2, ME1, ME3 ERN1 4286/4885NPC1 4549/4885RAB9A 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.